Navigating Recent Changes in Dosing Information: Dynamics of FDA‐Approved Monoclonal Antibodies in Post‐Marketing Realities
ABSTRACT Monoclonal antibodies (mAbs) are critical components in the therapeutic landscape, but their dosing strategies often evolve post‐approval as new data emerge. This review evaluates post‐marketing label changes in dosing information for FDA‐approved mAbs from January 2015 to September 2024, w...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Clinical and Translational Science |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/cts.70125 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832589802168385536 |
|---|---|
| author | Nai Lee Su‐jin Rhee Seong Min Koo So Won Kim Gyo Eun Lee Yoon A Yie Yun Kim |
| author_facet | Nai Lee Su‐jin Rhee Seong Min Koo So Won Kim Gyo Eun Lee Yoon A Yie Yun Kim |
| author_sort | Nai Lee |
| collection | DOAJ |
| description | ABSTRACT Monoclonal antibodies (mAbs) are critical components in the therapeutic landscape, but their dosing strategies often evolve post‐approval as new data emerge. This review evaluates post‐marketing label changes in dosing information for FDA‐approved mAbs from January 2015 to September 2024, with a focus on both initial and extended indications. We systematically analyzed dosing modifications, categorizing them into six predefined groups: Dose increases or decreases, inclusion of new patient populations by body weight or age, shifts from body weight‐based dosing to fixed regimens, and adjustments in infusion rates. Among the 86 mAbs evaluated, 21% (n = 18) exhibited changes in dosing information for the initial indication, with a median time to modification of 37.5 months (range: 5–76 months). Furthermore, for mAbs with extended indications (n = 26), 19.2% (n = 5) underwent dosing changes in their first extensions, with a median time to adjustment of 31 months (range: 8–71 months). Key drivers for these adjustments included optimizing therapeutic efficacy, addressing safety concerns, accommodating special populations, and enhancing patient convenience. We also discuss the role of model‐informed drug development, real‐world evidence, and pharmacogenomics in refining mAb dosing strategies. These insights underscore the importance of ongoing monitoring and data integration in the post‐marketing phase, providing a foundation for future precision medicine approaches in mAb therapy. |
| format | Article |
| id | doaj-art-dc20c0968b0a40638af258ddb5e62988 |
| institution | Kabale University |
| issn | 1752-8054 1752-8062 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Translational Science |
| spelling | doaj-art-dc20c0968b0a40638af258ddb5e629882025-01-24T08:17:46ZengWileyClinical and Translational Science1752-80541752-80622025-01-01181n/an/a10.1111/cts.70125Navigating Recent Changes in Dosing Information: Dynamics of FDA‐Approved Monoclonal Antibodies in Post‐Marketing RealitiesNai Lee0Su‐jin Rhee1Seong Min Koo2So Won Kim3Gyo Eun Lee4Yoon A Yie5Yun Kim6College of Pharmacy, Daegu Catholic University Gyeongsan KoreaCollege of Pharmacy, Wonkwang University Iksan KoreaCollege of Pharmacy, Daegu Catholic University Gyeongsan KoreaCollege of Pharmacy, Daegu Catholic University Gyeongsan KoreaCollege of Pharmacy, Daegu Catholic University Gyeongsan KoreaCollege of Pharmacy, Daegu Catholic University Gyeongsan KoreaCollege of Pharmacy, Daegu Catholic University Gyeongsan KoreaABSTRACT Monoclonal antibodies (mAbs) are critical components in the therapeutic landscape, but their dosing strategies often evolve post‐approval as new data emerge. This review evaluates post‐marketing label changes in dosing information for FDA‐approved mAbs from January 2015 to September 2024, with a focus on both initial and extended indications. We systematically analyzed dosing modifications, categorizing them into six predefined groups: Dose increases or decreases, inclusion of new patient populations by body weight or age, shifts from body weight‐based dosing to fixed regimens, and adjustments in infusion rates. Among the 86 mAbs evaluated, 21% (n = 18) exhibited changes in dosing information for the initial indication, with a median time to modification of 37.5 months (range: 5–76 months). Furthermore, for mAbs with extended indications (n = 26), 19.2% (n = 5) underwent dosing changes in their first extensions, with a median time to adjustment of 31 months (range: 8–71 months). Key drivers for these adjustments included optimizing therapeutic efficacy, addressing safety concerns, accommodating special populations, and enhancing patient convenience. We also discuss the role of model‐informed drug development, real‐world evidence, and pharmacogenomics in refining mAb dosing strategies. These insights underscore the importance of ongoing monitoring and data integration in the post‐marketing phase, providing a foundation for future precision medicine approaches in mAb therapy.https://doi.org/10.1111/cts.70125drug informationdrug safetydrug utilizationmonoclonal antibodiespharmacovigilance |
| spellingShingle | Nai Lee Su‐jin Rhee Seong Min Koo So Won Kim Gyo Eun Lee Yoon A Yie Yun Kim Navigating Recent Changes in Dosing Information: Dynamics of FDA‐Approved Monoclonal Antibodies in Post‐Marketing Realities Clinical and Translational Science drug information drug safety drug utilization monoclonal antibodies pharmacovigilance |
| title | Navigating Recent Changes in Dosing Information: Dynamics of FDA‐Approved Monoclonal Antibodies in Post‐Marketing Realities |
| title_full | Navigating Recent Changes in Dosing Information: Dynamics of FDA‐Approved Monoclonal Antibodies in Post‐Marketing Realities |
| title_fullStr | Navigating Recent Changes in Dosing Information: Dynamics of FDA‐Approved Monoclonal Antibodies in Post‐Marketing Realities |
| title_full_unstemmed | Navigating Recent Changes in Dosing Information: Dynamics of FDA‐Approved Monoclonal Antibodies in Post‐Marketing Realities |
| title_short | Navigating Recent Changes in Dosing Information: Dynamics of FDA‐Approved Monoclonal Antibodies in Post‐Marketing Realities |
| title_sort | navigating recent changes in dosing information dynamics of fda approved monoclonal antibodies in post marketing realities |
| topic | drug information drug safety drug utilization monoclonal antibodies pharmacovigilance |
| url | https://doi.org/10.1111/cts.70125 |
| work_keys_str_mv | AT nailee navigatingrecentchangesindosinginformationdynamicsoffdaapprovedmonoclonalantibodiesinpostmarketingrealities AT sujinrhee navigatingrecentchangesindosinginformationdynamicsoffdaapprovedmonoclonalantibodiesinpostmarketingrealities AT seongminkoo navigatingrecentchangesindosinginformationdynamicsoffdaapprovedmonoclonalantibodiesinpostmarketingrealities AT sowonkim navigatingrecentchangesindosinginformationdynamicsoffdaapprovedmonoclonalantibodiesinpostmarketingrealities AT gyoeunlee navigatingrecentchangesindosinginformationdynamicsoffdaapprovedmonoclonalantibodiesinpostmarketingrealities AT yoonayie navigatingrecentchangesindosinginformationdynamicsoffdaapprovedmonoclonalantibodiesinpostmarketingrealities AT yunkim navigatingrecentchangesindosinginformationdynamicsoffdaapprovedmonoclonalantibodiesinpostmarketingrealities |